C12N 2750/14321
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2750/14321 (Viruses as such) appears on 12 US grants and 23 published applications in this corpus.
Search patents in C12N- Granted patents
- 12
- Published applications
- 23
- Assignees
- 21
- Inventors
- 61
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 2 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 1 | 1 |
| 2015 | 0 | 2 |
| 2016 | 1 | 1 |
| 2017 | 1 | 2 |
| 2018 | 2 | 0 |
| 2019 | 1 | 2 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 2 | 2 |
| 2023 | 1 | 2 |
| 2024 | 1 | 2 |
| 2025 | 0 | 1 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs16 Jun 2026US 12,655,427 B2Research Institute At Nationwide Children's Hospital
- cis and trans requirements for terminal resolution of human bocavirus 124 Dec 2024US 12,173,305 B2University of Iowa Research Foundation
- Triple live vaccine of canine distemper virus, canine parvovirus and canine infectious hepatitis virus30 May 2023US 11,660,337 B2Liaoning Yikang Biological Corporation Limited
- Method to homogenize parvovirus B19 in clinical samples8 Feb 2022US 11,242,571 B2Grifols Diagnostic Solutions Inc.
- Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs25 Jan 2022US 11,230,707 B2Research Institute At Nationwide Children's Hospital
- Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs3 Sep 2026US 2026/0258419 A1Research Institute At Nationwide Children's Hospital
- Cis and trans requirements for terminal resolution of human bocavirus 130 Apr 2026US 2026/0117253 A1University of Iowa Resarch Foundation
- Modified oncolytic parvovirus h-1pv with an enhanced fitness and superior anticancer activity21 Aug 2025US 2025/0262296 A1
- Viral clearance test method30 May 2024US 2024/0175098 A1Asahi Kasei Medical Co., Ltd.
- Pharmaceutical combination product comprising a protoparvovirus and an antiviral benzimidazole and uses thereof for treating cancer8 Feb 2024US 2024/0041833 A1Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Most cited
By later US patents
- Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs8US 9,862,945 B2Research Institute At Nationwide Children's Hospital · 2018
- Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs3US 11,230,707 B2Research Institute At Nationwide Children's Hospital · 2022
- Isolation of a virus related to canine parvovirus-2 from a raccoon2US 8,734,808 B2The Board of Regents for Oklahoma State University · 2014